{"id":"NCT03631732","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","officialTitle":"A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-28","primaryCompletion":"2019-08-12","completion":"2020-08-19","firstPosted":"2018-08-15","resultsPosted":"2020-08-27","lastUpdate":"2021-09-05"},"enrollment":496,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"B/F/TAF","otherNames":["Biktarvy®"]},{"type":"DRUG","name":"NRTIs","otherNames":[]},{"type":"DRUG","name":"Third Agent","otherNames":[]}],"arms":[{"label":"B/F/TAF","type":"EXPERIMENTAL"},{"label":"Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing their baseline regimen in HIV-1 infected, virologically suppressed African American participants.","primaryOutcome":{"measure":"Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set","timeFrame":"Week 24","effectByArm":[{"arm":"B/F/TAF","deltaMin":0.6,"sd":null},{"arm":"Stay on Baseline Regimen (SBR)","deltaMin":1.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.3399"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":15},"locations":{"siteCount":82,"countries":["United States"]},"refs":{"pmids":["34397746"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":330},"commonTop":["Upper respiratory tract infection","Syphilis","Diarrhoea","Pain in extremity"]}}